Allen Institute Overview

  • Founded

  • 2003

Founded
  • Status

  • Private

  • Employees

  • 216

Employees
  • Latest Deal Type

  • Later Stage VC

  • Latest Deal Amount

  • $30M

  • Investors

  • 5

Allen Institute General Information

Description

Operator of a biotechnology company intended to solve mysteries of bioscience. The company offers a platform for researchers to understand the working of the human brain in health and diseases, enabling physicians to treat their patients in an enhanced way.

Contact Information

Website
www.alleninstitute.org
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Other Services (B2C Non-Financial)
Primary Office
  • 615 Westlake Avenue North
  • Seattle, WA 98109
  • United States
+1 (206) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Allen Institute Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
3. Later Stage VC 12-May-2023 $30M 00000 Completed Generating Revenue
2. Grant 06-Oct-2014 00.00 00000 Completed Generating Revenue
1. Capitalization 01-Jan-2003 $500M $500M Completed Startup
To view Allen Institute’s complete valuation and funding history, request access »

Allen Institute Patents

  • 57

    Total Documents Applications and Grants

  • 000

    Total Patents Families

  • 3

    Granted

  • 11

    Pending

  • 000

    Expiring in next 12 mo

Allen Institute Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2021324975-A1 Artificial expression constructs for modulating gene expression in striatal neurons Pending 14-Aug-2020 0000000000
CA-3186367-A1 Artificial expression constructs for modulating gene expression in striatal neurons Pending 14-Aug-2020 0000000000
AU-2021284465-A1 Artificial expression constructs for selectively modulating gene expression in inhibitory neocortical neurons Pending 04-Jun-2020 00000000000
CA-3180017-A1 Artificial expression constructs for selectively modulating gene expression in inhibitory neocortical neurons Pending 04-Jun-2020 00000000000
EP-4162041-A2 Artificial expression constructs for selectively modulating gene expression in inhibitory neocortical neurons Pending 04-Jun-2020 A61K48/0058
To view Allen Institute’s complete patent history, request access »

Allen Institute Executive Team (16)

Name Title Board Seat Contact Info
Rui Costa Ph.D Chief Executive Officer & President
Allan Jones Ph.D President Emeritus
Marjorie Thomas Chief Financial Officer
Chris Beaudoin Chief Operating Officer
Princess Ayers-Stewart Chief Diversity & Belonging Officer
You’re viewing 5 of 16 executive team members. Get the full list »

Allen Institute Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Allen Institute Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Evergreen/GaveKal Corporation Minority 000 0000 000000 0
Khosla Ventures Venture Capital Minority 000 0000 000000 0
Madrona Venture Labs Accelerator/Incubator Minority 000 0000 000000 0
Sequoia Capital Venture Capital Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
To view Allen Institute’s complete investors history, request access »

Ready to get started?

Request a free trial